The company’s participation includes both the virtual session and a series of one-on-one meetings with investors in New York. Interested parties can access a live webcast of the presentation through the investor relations section of the Tyra Biosciences website, where a replay will also be hosted following the event.
Tyra Biosciences Schedules Investor Presentation at Cantor Conference
Tyra Biosciences will present its latest clinical developments during a virtual fireside chat at the 2026 Cantor Global Healthcare Conference. The Carlsbad-based biotechnology firm, which specializes in precision medicines targeting FGFR biology, is scheduled to discuss its pipeline on Wednesday, September 9, 2026, at 1:00 PM ET.
Tyra Biosciences continues to advance its proprietary SNÅP platform, which facilitates rapid drug design through iterative molecular snapshots. The firm’s current development efforts center on three primary candidates: the FGFR3 inhibitor dabogratinib, the FGFR4/3-biased inhibitor TYRA-430 for hepatocellular carcinoma, and the FGFR1/2/3 inhibitor TYRA-200, currently under investigation for metastatic intrahepatic cholangiocarcinoma.
Comments (0)
No comments yet. Be the first!